Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT01817530 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01817530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01817530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2013
Completion date
December 31, 2015
Enrollment
571 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heavy uterine bleeding, uterine fibroids